Quanterix (QTRX) Q3 2024 earnings summary

Executive summary

• Achieved sixth consecutive quarter of double-digit revenue growth, with Q3 2024 revenue up 13% year-over-year to $35.8 million, driven by strong Accelerator Lab, consumables, and service revenue, while instrument sales declined.

• Reaffirmed full-year 2024 revenue guidance and continued expansion in Alzheimer's diagnostics, neurology, and immunology product lines.

• Announced and completed restatement of prior period financials due to inventory valuation errors and internal control weaknesses, with no material impact expected on total revenues or cash.

• Announced acquisition of Emission Inc. for up to $70 million to expand multiplex assay and OEM market capabilities.

• Launched LucentAD Complete, a multi-marker Alzheimer's blood test, and expanded global partnerships, including significant progress in China and new board appointments.

Financial highlights

• Q3 2024 total revenue: $35.8 million (+13% YoY); GAAP gross margin: 58.9%; non-GAAP gross margin: 53.4%.

• Q3 2024 net loss: $8.4 million; operating loss (restated GAAP): $(11.2) million.

• Cash, cash equivalents, and securities at quarter-end: $296.1 million; Q3 cash outflow: $3.3 million.

• Service revenue for Q3 2024: $13.8 million (+27% YoY); collaboration and license revenue: $1.9 million (+690% YoY).

• Operating expenses for Q3 2024 were $31.9 million, flat year-over-year; R&D expense increased 5% YoY.

Outlook and guidance

• Reaffirmed 2024 revenue guidance of $134–$138 million, excluding Lucent Diagnostics testing revenue.

• GAAP gross margin guidance: 57–61%; non-GAAP gross margin: 51–55%.

• Cash burn guidance unchanged at ~$30 million for 2024; cash position expected to be sufficient for at least 12 months.

• Research-use only business expected to reach cash flow break-even at $170–$190 million revenue.

• No material revenue expected from Lucent Diagnostics tests until 2025 or later.